FDA Determines Regulatory Review Period for VOQUEZNA DUAL PAK New Drug Application

Summary

The US Food and Drug Administration (FDA) has set a regulatory review period for VOQUEZNA DUAL PAK, a new drug application (NDA 215153), following a request from the US Patent and Trademark Office (USPTO) to extend a patent claiming the human drug product.